Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer

Launched by UNIVERSITY HOSPITAL TUEBINGEN · Sep 11, 2012

Keywords

ClinConnect Summary

The gastric carcinoma is one of the four most common tumors occurring worldwide. The advanced phase is characterized by metastasis and poses a very poor prognosis for survival. In 20%-30% of gastric carcinomas the tumor spreads into the abdominal cavity, which leads to metastases in the wall of the peritoneal cavity. This is known as peritoneal carcinomatosis and its five-year survival rate is less than 2%. Even after R0 resection of a localized gastric carcinoma the five-year survival rate is only 40%, not least of all because relapses in the form of peritoneal metastases are a common occu...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically proven gastric adenocarcinoma: uT1,uT2, uT3, Nx, M0
• • 2. No prior chemotherapy
• • 3. Patients of full age, independent of gender ECOG ≤ 2
• • 4. No dissemination of the tumor confirmed by CT of the lung and the abdomen.
• • 5. Signed Consent form of the Patient agreeing to investigations
• • 6. Leucocytes \> 3.000/µl
• • 7. Thrombocytes \> 100.000/µl
• • 8. Creatinine ≤ 1.5mg/dl and or Clearance \> 60 ml/min
• • 9. informed consent of the patient
• • 10. normal ejection-fraction of the heart
• Exclusion Criteria:
• • 1. Dissemination of the tumor or non-resectable primary tumor
• • 2. Malignant secondary disease \< 5 years in the past (Exception: in-situ-carcinoma of the cervix and appropriately treated basal cell carcinoma of the skin)
• • 3. Patient not of full age
• • 4. Inflammatory chronic bowel disease
• • 5. Inclusion of the patient in a different study
• • 6. Pregnancy or lactation